GlassScriptPhysician profile
Adam B Stern
NPI 1376769893
$5,704.44
in general payments reported to CMS, 2019-2025
33 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2020: $431 · 2021: $380 · 2022: $745 · 2023: $883 · 2024: $1,123 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,026 · Education: $4.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,025.89 |
| Education | $4.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $926.52 | 2019-2025 | Jynarque |
| Amgen INC. | $677.13 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $399.79 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $360.85 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $313.32 | 2022-2025 | Acthar |
| Fresenius USA Marketing, INC. | $291.81 | 2019-2025 | Korsuva, Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $251.14 | 2021-2025 | |
| Ardelyx, INC. | $231.42 | 2023-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $216.25 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $193.12 | 2019-2025 | Veltassa |
| Travere Therapeutics, INC. | $193.05 | 2022-2025 | |
| Akebia Therapeutics INC | $187.89 | 2019-2024 | Auryxia, Vafseo |
| Bard Peripheral Vascular, INC. | $170.19 | 2019-2020 | |
| Novo Nordisk INC | $169.79 | 2023-2025 | Ozempic, Rivfloza, Rybelsus |
| Novartis Pharmaceuticals Corporation | $168.86 | 2023-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $139.70 | 2021-2024 | Ultomiris, Soliris |
| Opko Pharmaceuticals, LLC | $124.12 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $76.74 | 2019 | |
| Glaxosmithkline, LLC. | $72.17 | 2022-2024 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.86 | 2023-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $64.49 | 2022-2023 | Lupkynis |
| Genzyme Corporation | $61.58 | 2019-2023 | |
| Daiichi Sankyo INC. | $54.41 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $46.97 | 2019 | |
| Scpharmaceuticals INC. | $45.02 | 2025 | |
| Ani Pharmaceuticals, INC. | $42.57 | 2022-2023 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $39.74 | 2025 | Empaveli |
| W. L. Gore & Associates, INC. | $29.36 | 2022 | |
| Shire North American Group INC | $21.40 | 2019 | |
| Lilly USA, LLC | $18.28 | 2025 | Jardiance |
| Cardiovascular Systems INC. | $18.23 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.85 | 2020 | |
| Mozarc Medical US LLC | $15.82 | 2023 | Palindrome |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.